Cargando…

A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19

BACKGROUND: There is an urgent need for treatments of mild or moderate COVID-19 in an outpatient setting. METHODS: A randomized double-blind placebo-controlled clinical trial in 36 centers in the U.S. between August 2020 and February 2021 investigated the safety and effectiveness of oral nitazoxanid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rossignol, Jean-François, Bardin, Matthew C., Fulgencio, Jessica, Mogelnicki, Dena, Bréchot, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883002/ https://www.ncbi.nlm.nih.gov/pubmed/35237748 http://dx.doi.org/10.1016/j.eclinm.2022.101310

Ejemplares similares

A Pilot Clinical Trial of Nitazoxanide in the Treatment of Chronic Hepatitis B
por: Rossignol, Jean‐François, et al.
Publicado: (2019)

Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial
por: Haffizulla, Jason, et al.
Publicado: (2014)

Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial.
por: Blum, Vinicius Fontanesi, et al.
Publicado: (2021)

Nitazoxanide in Patients Hospitalized With COVID-19 Pneumonia: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial
por: Rocco, Patricia R. M., et al.
Publicado: (2022)

Nitazoxanide: A first-in-class broad-spectrum antiviral agent
por: Rossignol, Jean-François
Publicado: (2014)

A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate COVID-19
por: Fowotade, Adeola, et al.
Publicado: (2022)

Corrigendum to “Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial.” [EClinicalMedicine 37 (2021) 100981]
por: Blum, Vinicius Fontanesi, et al.
Publicado: (2021)

Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
por: Rossignol, Jean-François
Publicado: (2016)

Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial
por: Rocco, Patricia R.M., et al.
Publicado: (2021)

The Modulation of Cholesterol Metabolism Is Involved in the Antiviral Effect of Nitazoxanide
por: Fenizia, Claudio, et al.
Publicado: (2021)

Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial
por: Dubée, Vincent, et al.
Publicado: (2021)

Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)
por: Aisen, Paul S., et al.
Publicado: (2011)

Sodium Hypochlorite 0.005% Versus Placebo in the Treatment of Mild to Moderate Acne: A Double-Blind Randomized Controlled Trial
por: Dorostkar, Azadeh, et al.
Publicado: (2021)

The effect of Melissa officinalis syrup on patients with mild to moderate psoriasis: a randomized, double-blind placebo-controlled clinical trial
por: Yargholi, Alireza, et al.
Publicado: (2021)

Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial
por: Manomaipiboon, Anan, et al.
Publicado: (2022)

Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)
por: Smith, Tania, et al.
Publicado: (2022)

Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial
por: Henderson, Samuel T, et al.
Publicado: (2009)

A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis
por: Cai, Lin, et al.
Publicado: (2020)

Photobiomodulation Improves Serum Cytokine Response in Mild to Moderate COVID-19: The First Randomized, Double-Blind, Placebo Controlled, Pilot Study
por: Marashian, Seyed Mehran, et al.
Publicado: (2022)

Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial
por: Wada, Tatsuhiko, et al.
Publicado: (2023)

Correction: Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)
por: Smith, Tania A., et al.
Publicado: (2023)

NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease
por: Lawlor, Brian, et al.
Publicado: (2014)

Early Life Interventions for Childhood Growth and Development in Tanzania (ELICIT): a protocol for a randomised factorial, double-blind, placebo-controlled trial of azithromycin, nitazoxanide and nicotinamide
por: DeBoer, Mark Daniel, et al.
Publicado: (2018)

ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension
por: Gault, Laura M., et al.
Publicado: (2016)

A phase II, double blind, placebo-controlled, randomized evaluation of the safety and efficacy of tafenoquine in patients with mild-moderate COVID-19 disease
por: Dow, G.-S., et al.
Publicado: (2022)

Efficacy and safety of polyherbal formulation as an add-on to standard-of-care in mild-to-moderate COVID-19: A randomized, double-blind, placebo-controlled trial
por: Patankar, Suresh B., et al.
Publicado: (2022)

Erratum: Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial
Publicado: (2023)

LB1528. Results from ACTIV-6: A Decentralized, Double-Blinded, Randomized, Placebo-Controlled Platform Trial of Repurposed Drugs for the Treatment of Mild-to-Moderate COVID-19
por: McCarthy, Matthew W
Publicado: (2022)

Effect of Linum usitatissimum L. (linseed) oil on mild and moderate carpal tunnel syndrome: a randomized, double-blind, placebo-controlled clinical trial
por: Hashempur, Mohammad Hashem, et al.
Publicado: (2014)

A Randomized, Double-Blind, Placebo-Controlled Study of a Novel Pantothenic Acid-Based Dietary Supplement in Subjects with Mild to Moderate Facial Acne
por: Yang, Michael, et al.
Publicado: (2014)

A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate COVID-19
por: Nicastri, Emanuele, et al.
Publicado: (2022)

Effects of probiotic supplements on cognition, anxiety, and physical activity in subjects with mild and moderate Alzheimer’s disease: A randomized, double-blind, and placebo-controlled study
por: Akhgarjand, Camellia, et al.
Publicado: (2022)

Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trial
por: Farahani, Ramin Hamidi, et al.
Publicado: (2023)

521. A phase II, double blind, placebo-controlled, randomized evaluation of the safety and efficacy of tafenoquine in patients with mild-moderate COVID-19 disease
por: Dow, Geoffrey
Publicado: (2023)

Methylphenidate for Mild Cognitive Impairment: An Exploratory 3-Day, Randomized, Double-Blind, Placebo-Controlled Trial
por: Press, Yan, et al.
Publicado: (2021)

Efficacy and Safety of Nitazoxanide, Albendazole, and Nitazoxanide-Albendazole against Trichuris trichiura Infection: A Randomized Controlled Trial
por: Speich, Benjamin, et al.
Publicado: (2012)

A double blind randomized placebo control crossover trial on the effect of dietary nitrate supplementation on exercise tolerance in stable moderate chronic obstructive pulmonary disease
por: Leong, Paul, et al.
Publicado: (2015)

Efficacy of colchicine in patients with moderate COVID-19: A double-blinded, randomized, placebo-controlled trial
por: Rahman, Motlabur, et al.
Publicado: (2022)

Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: Results from a randomized double blind placebo controlled trial
por: Kedia, Saurabh, et al.
Publicado: (2017)

A randomized, double-blind, placebo-controlled trial for Yi-Qi Hua-Yu tong-sui granule in the treatment of mild or moderate cervical spondylotic myelopathy
por: Xu, Chongqing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_319h1gpl94s512a9phq2q6bvm4